Cited 6 times in
Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.date.accessioned | 2020-09-29T01:11:53Z | - |
dc.date.available | 2020-09-29T01:11:53Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 0300-7995 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/179434 | - |
dc.description.abstract | Background: Given a hepatitis C virus (HCV) elimination goal by 2030, World Health Organization (WHO) guidelines recommend scaling up HCV screening and treatment with highly-effective direct-acting antivirals (DAAs). This study investigated the cost-effectiveness of various screening and treatment strategies for chronic HCV patients in South Korea in patients aged over 40 as compared to currently screening only high-risk patients.Methods: A published Markov disease progression model was used with a screening/treatment decision-tree to model different screening and treatment strategies for Korean HCV patients (aged over 40) from a national payer perspective over a lifetime time horizon. The screening strategies included "screen-all" (upfront only: "once"; or upfront and age 65: "twice") or a "high-risk only" screening strategy followed by treatment. Treatment strategies included either ledipasvir/sofosbuvir (LDV/SOF), SOF + ribavirin (SOF + RBV; in GT2 only), or glecaprevir/pibrentasvir (GLE/PIB). Model inputs were sourced from published literature and costing databases and validated by Korean hepatologists.Results: Regardless of treatment strategy, a "screen all twice" scenario led to the lowest rates of advanced liver disease events compared to "screen all once" and "high-risk only" screening scenarios. In this screening scenario, treatment with LDV/SOF for GT1/2 dominates (i.e. is more effective and less4costly) LDV/SOF in GT1 and SOF + RBV in GT2, while GLE/PIB is not cost-effective relative to LDV/SOF (₩105,124,920/QALY) at a willingness-to-pay threshold of 1xGDP per capita.Conclusion: Screening all South Korean patients twice followed by LDV/SOF treatment is cost-effective as compared current high-risk screening. Adopting this strategy can help achieve WHO HCV elimination goals. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isPartOf | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Gabriel Wong | - |
dc.contributor.googleauthor | Janet Lee | - |
dc.contributor.googleauthor | Myung Hwa Kim | - |
dc.contributor.googleauthor | Nathaniel Smith | - |
dc.contributor.googleauthor | Rob Blissett | - |
dc.contributor.googleauthor | Hyung Joon Kim | - |
dc.identifier.doi | 10.1080/03007995.2020.1756232 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J00667 | - |
dc.identifier.eissn | 1473-4877 | - |
dc.identifier.pmid | 32295431 | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/03007995.2020.1756232 | - |
dc.subject.keyword | Hepatitis C | - |
dc.subject.keyword | South Korea | - |
dc.subject.keyword | cost-effectiveness | - |
dc.subject.keyword | cost-utility | - |
dc.subject.keyword | glecaprevir/pibrentasvir | - |
dc.subject.keyword | ledipasvir/sofosbuvir | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.citation.volume | 36 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 993 | - |
dc.citation.endPage | 1002 | - |
dc.identifier.bibliographicCitation | CURRENT MEDICAL RESEARCH AND OPINION, Vol.36(6) : 993-1002, 2020-06 | - |
dc.identifier.rimsid | 67443 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.